Table 1 Patient baseline characteristics and transplant details

Total number of adult patients

39

Median (range) age (years)

35 (18–59)

Gender (%)

32 (82%) female

Disease subtype

39 (100%) diffuse

Median (range) disease duration (years)^a

2 (0.5-14)

 Skin, n (%)

39/39 (100%)

 mRSS units, median (range)

24 (8–50)

 Interstitial lung disease, n (%)

28/39 (71.79%)

 Pulmonary hypertension, n (%)

3/39 (7.6 %) mild

 Forced vital capacity, % of predicted, mean (SD)

74.68 (32.5)

 Heart involvement, n (%)^b

16/39 (40.9%)

 Esophageal dysmotility, n (%)

36/39 (92.30%)

 Kidney, n

0

 Positive anti-Scl-70 antibodies, n (%)

26/39 (66.6%)

 Methotrexate, n (%)

17/39 (43.1 %)

 Cyclophosphamide, n (%)

29/39 (74.4 %)

 Mycophenolate mofetil, n (%)

8/39 (20.5 %)

 Rituximab, n (%)

2/39 (5.1 %)

 Cyclophosphamide + ATG

36/39 (92.3%)

 Fludarabine + Melphalan + ATG

3/39 (7.7 %)